托珠单抗治疗早期系统性硬化相关间质性肺病的长期安全性与疗效
本文为3期随机对照试验的开放标签扩展研究,评估托珠单抗治疗早期系统性硬化(SSc)相关间质性肺病的长期安全性与疗效。结果显示托珠单抗可减缓FVC下降、保留肺功能,长期安全性与已知特征一致。
要点
- 托珠单抗可减缓SSc患者FVC下降,包括合并ILD者
- 96周内严重不良事件发生率与既往安全性特征一致
- 安慰剂转托珠单抗与持续托珠单抗两组均完成96周随访
核心结论
- 托珠单抗在SSc患者(包括合并ILD者)中保留肺功能、减缓FVC下降,长期安全性与已知安全性特征一致。
研究设计与样本
- 3期随机对照试验的开放标签扩展研究,双盲期48周后开放标签托珠单抗至96周(安慰剂-托珠单抗组与持续-托珠单抗组)。
- 入组为弥漫性皮肤型SSc病程≤60个月且急性期反应物升高的成人,高分辨率CT显示ILD者占61%。
主要发现
- 基线至96周改良Rodnan皮肤评分平均变化:安慰剂-托珠单抗组-8.4(95%CI -10.0至-6.8),持续-托珠单抗组-9.6(95%CI -10.9至-8.4)。
- 完成者基线至96周FVC(占预计值百分比)平均变化:安慰剂-托珠单抗组-3.3(95%CI -5.1至-1.5),持续-托珠单抗组-0.5(95%CI -2.4至1.3)。
- 事后分析中合并ILD的完成者FVC平均变化:安慰剂-托珠单抗组-4.1(95%CI -6.7至-1.6),持续-托珠单抗组-0.6(95%CI -3.1至2.0)。
- 第48至96周每100患者年严重不良事件发生率:安慰剂-托珠单抗组14.8,持续-托珠单抗组15.8。
临床怎么用
- 对早期弥漫性皮肤型SSc合并ILD且急性期反应物升高的患者,托珠单抗可作为减缓肺功能下降的长期治疗选择之一。
- 长期用药期间需按已知安全性特征监测严重不良事件。
局限性
- 开放标签扩展研究缺乏随机对照,长期疗效证据强度有限。
- ILD相关FVC结果为事后分析,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Tocilizumab, an anti-IL-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis (SSc)-associated interstitial lung disease (ILD) in a phase 3 randomized controlled trial. Objectives: Assess long-term safety and efficacy of tocilizumab. Methods: Adults with diffuse cutaneous SSc for ⩽60 months and elevated acute-phase reactants, including those with ILD, received weekly placebo or tocilizumab 162 mg subcutaneously in the 48-week, double-blind period and then open-label tocilizumab from Weeks 48 to 96 (placebo-tocilizumab; continuous-tocilizumab). Measurements and Main Results: Eighty-two of 107 patients in the placebo-tocilizumab group and 85 of 105 patients in the continuous-tocilizumab group completed 96 weeks. Mean age and disease duration were 48 years and 23 months; high-resolution computed tomography revealed ILD in 61%. Mean (95% confidence interval [CI]) change in modified Rodnan skin score from baseline to week 96 was -8.4 (-10.0 to -6.8) for placebo-tocilizumab and -9.6 (-10.9 to -8.4) for continuous-tocilizumab. Mean (95% CI) change in FVC (percent predicted) from baseline to week 96 was -3.3 (-5.1 to -1.5) for placebo-tocilizumab and -0.5 (-2.4 to 1.3) for continuous-tocilizumab among completers and, in a post hoc analysis, -4.1 (-6.7 to -1.6) and -0.6 (-3.1 to 2.0), respectively, among completers with ILD (mean [95% CI] change from Weeks 48 to 96: 0.9 [-0.8 to 2.7] and -0.4 [-2.3 to 1.5], respectively). Rates per 100 patient-years of serious adverse events from Weeks 48 to 96 were 14.8 for placebo-tocilizumab and 15.8 for continuous-tocilizumab. Conclusions: Tocilizumab preserved lung function, slowing decline in FVC, in patients with SSc, including those with ILD. Long-term safety was consistent with the known safety profile of tocilizumab. Clinical trial registered with www.clinicaltrials.gov (NCT02453256).
引用
- Khanna D, Lin CJF, Furst DE, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022. PMID: 34851799. doi:10.1164/rccm.202103-0714OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。